Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 26.03M 18.36M 16.01M 14.83M 13.88M 1.73B 26.19M 176M 68.17M 853M 68.92M 67.44M 2.96B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 25.8M 18.2M 15.87M 14.69M 13.76M 1.72B 25.95M 174M 67.56M 845M 68.31M 66.84M 2.93B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.03%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 30/06/2019
Director of Finance/CFO - 16/08/2022
Chief Tech/Sci/R&D Officer - 16/09/2024
Director TitleAgeSince
Director/Board Member - 05/12/2017
Director/Board Member - 30/06/2019
Chairman - 29/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+7.14% - - 18.36M
-1.21%-3.04%+44.03%+142.51% 980B
-2.48%-5.18%+52.47%+39.36% 550B
-2.14%-4.94%+16.83%+58.18% 382B
+0.25%-3.09%+23.33%+16.78% 316B
+0.61%-1.69%+27.35%+14.22% 272B
+0.22%-3.10%+24.67%+30.69% 268B
+4.59%+1.98%-38.43%-46.41% 199B
-1.19%-4.95%+16.68%+48.70% 182B
-1.35%-1.46%+14.06%+59.46% 154B
Average -0.27%-3.02%+20.11%+40.39% 366.93B
Weighted average by Cap. -0.78%-3.68%+29.49%+63.49%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.78 0.01 0.08 0.03 0.38 0.03 0.03 1.33
Net income -1.71M -1.2M -1.05M -972K -910K -114M -1.72M -11.54M -4.47M -55.93M -4.52M -4.42M -194M -3.53M -2.49M -2.17M -2.01M -1.88M -235M -3.55M -23.87M -9.25M -116M -9.35M -9.15M -402M
Net Debt -113K -79.45K -69.27K -64.15K -60.06K -7.5M -113K -761K -295K -3.69M -298K -292K -12.81M -231K -163K -142K -131K -123K -15.34M -232K -1.56M -604K -7.55M -610K -597K -26.23M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!